Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
News|Articles|July 2, 2025
FDA News Recap: Novel Drug Approvals in First Half of 2025
Author(s)Abigail Brooks, MA
Fact checked by: Chelsie Derman
A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.
Advertisement
Advertisement
The first half of 2025 brought a wave of innovation across the medical community, with 16 novel drug approvals signaling major strides in disease treatment and management across a wide range of specialties.
Related to this article
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Advertisement
Advertisement